Previous 10 | Next 10 |
2024-06-05 09:00:17 ET Summary Structure Therapeutics Inc.'s oral GLP-1 agonist, GSBR-1290, showed a 6.2% mean weight loss over 12 weeks, significantly outperforming placebo. Adverse events were high, with 89.2% experiencing nausea and 62.2% vomiting. The financial outlook is ...
2024-06-05 08:10:19 ET More on Eli Lilly Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Eli Lilly: Addressing Supply Challenges Should Accelerate Growth Eli Lilly CFO Anat Ashkenaz...
2024-06-04 15:40:11 ET More on Viking Therapeutics What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired Viking Therapeutics, Inc. (VKTX) Q1 2024 Earnings Call Transcrip...
2024-06-04 13:59:40 ET Viking Therapeutics Inc (NASDAQ: VKTX) is in focus today after announcing positive Phase 2b data for its treatment for biopsy-confirmed non-alcoholic steatohepatitis (NASH). $VKTX’s drug did significantly better than placebo VK2809 of the biotech fi...
2024-06-04 09:22:09 ET More on related stocks Intel's Goldman Sach's Meeting Yields Interesting Information Intel: Capitalize On The Downtrend Computex Chronicles Part 2: AMD Leaps Into Copilot+ PCs And Outlines Infrastructure GPU Roadmap Nvidia, DraftKings, ...
2024-06-04 08:07:00 ET More on Viking Therapeutics What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired Viking Therapeutics, Inc. (VKTX) Q1 2024 Earnings Call Transcrip...
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) PR Newswire Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibros...
2024-06-03 10:15:00 ET Even if you're not an investor like Cathie Wood, who specializes in businesses that claim to have a shot at disrupting their industries, investing in aspiring disruptors can be a great tactic to shore up your portfolio's exposure to growth. Assuming you can tolerate t...
2024-06-02 10:00:00 ET More on Amgen, Structure Therapeutics, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? ...
2024-05-31 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are plenty of underappreciated stocks on the market. Look at Viking Therapeutics (NASDAQ: VKTX ), for example. When I first highlighted VKTX on June 22, 2023 , it ...
News, Short Squeeze, Breakout and More Instantly...
Viking Therapeutics Inc. Company Name:
VKTX Stock Symbol:
NASDAQ Market:
Viking Therapeutics Inc. Website:
2024-07-15 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 05:42:00 ET Viking Therapeutics (NASDAQ: VKTX) has been one of the hottest healthcare stocks to own this year, thanks to hype and excitement relating to its promising weight loss treatment, VK2735. The potential that investors see in the drug is a key reason the stock h...
2024-07-10 06:41:00 ET Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) are a pair of biotechs planning to follow in the footsteps of Novo Nordisk and Eli Lilly and develop GLP-1-targeted medicines for obesity like Wegovy and Zepbound. Both companies ha...